Collegium buys Ironshore for $525m and enter ADHD market [Yahoo! Finance]
Cingulate Inc. (CING)
Company Research
Source: Yahoo! Finance
Collegium will pay $525m in cash to acquire outstanding shares of Ironshore. Following the transaction, Collegium will gain Ironshore's US Food and Drug Administration (FDA)-approved therapy, Jornay PM (methylphenidate hydrochloride), for treating attention deficit hyperactivity disorder (ADHD) in patients aged six years and older. The company will also pay an additional $25m if the sales of Jornay PM exceed Collegium's defined revenue expectations in 2025. The deal is expected to close in Q3 this year. Concurrent with the acquisition, Collegium also secured $646m as part of a five-year loan from Pharmakon Advisors, which, along with Collegium's cash reserves, will fund the Ironshore acquisition. “The Ironshore acquisition is a unique opportunity to deliver a transaction that is immediately accretive to Collegium while meeting all of our strategic objectives through the addition of a growing commercial asset that diversifies our portfolio, has significant revenue potential and ex
Show less
Read more
Impact Snapshot
Event Time:
CING
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CING alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CING alerts
High impacting Cingulate Inc. news events
Weekly update
A roundup of the hottest topics
CING
News
- Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301GlobeNewswire
- Cingulate to Participate in Benzinga All Live Access EventGlobeNewswire
- Cingulate Announces Adjournment of Special MeetingGlobeNewswire
- Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones AchievedGlobeNewswire
CING
Sec Filings
- 9/27/24 - Form S-1
- 9/12/24 - Form 8-K
- 9/10/24 - Form 8-K
- CING's page on the SEC website